153Sm-edtmp combined with docetaxel in patients with hormone-refractory metastatic prostate cancer:: preliminary data on toxicity and response

被引：0
|
作者：
Boni, G.
Pastina, I.
Genovesi, D.
Chioni, A.
Cianci, C.
Pesella, F.
Picchi, G.
Ricci, S.
Mariani, G.
机构：
[1] Univ Pisa, Azienda Osped, Ctr Med Nucl, Pisa, Italy
[2] Univ Pisa, Azienda Osped, Pisa, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S195 / S196
页数：2
相关论文
共 50 条
  • [1] Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
    Marnix G. E. H. Lam
    Amel Dahmane
    Wil H. M. Stevens
    Peter P. van Rijk
    John M. H. de Klerk
    Bernard A. Zonnenberg
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 756 - 765
  • [2] Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
    Lam, Marnix G. E. H.
    Dahmane, Amel
    Stevens, Wil H. M.
    Van Rijk, Peter P.
    de Klerk, John M. H.
    Zonnenberg, Bernard A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (04) : 756 - 765
  • [3] Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
    Ricci, Sergio
    Boni, Giuseppe
    Pastina, Ilaria
    Genovesi, Dario
    Cianci, Claudia
    Chiacchio, Serena
    Orlandini, Cinzia
    Grosso, Mariano
    AlSharif, Abedallatif
    Chioni, Aldo
    Di Donato, Samantha
    Francesca, Francesco
    Selli, Cesare
    Rubello, Domenico
    Mariani, Giuliano
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (07) : 1023 - 1030
  • [4] Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
    Sergio Ricci
    Giuseppe Boni
    Ilaria Pastina
    Dario Genovesi
    Claudia Cianci
    Serena Chiacchio
    Cinzia Orlandini
    Mariano Grosso
    Abedallatif AlSharif
    Aldo Chioni
    Samantha Di Donato
    Francesco Francesca
    Cesare Selli
    Domenico Rubello
    Giuliano Mariani
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 1023 - 1030
  • [5] Bone palliation therapy with 153Sm-EDTMP combined with chemotherapy ensues objective clinical benefit in patients with metastatic, hormone-refractory prostatic cancer.
    Boni, G
    Ricci, S
    Pastina, I
    Grosso, M
    Cresti, N
    Chiacchio, S
    Galli, L
    Alsharif, A
    Mariani, B
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 412P - 412P
  • [6] The SAMDOCET study: 153Sm-EDTMP and Docetaxel versus Docetaxel in Taxane-naive patients with metastatic castrationrefractory prostate cancer.
    Borso, E.
    Mazzarri, S.
    Boni, G.
    Cianci, C.
    Tosi, D.
    Sansovini, M.
    Baldari, S.
    Vuillez, J.
    Morel, O.
    Veltri, M.
    Schiavo, R.
    Orlandini, C.
    Ricci, S.
    Mariani, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S497 - S497
  • [7] Docetaxel in hormone-refractory metastatic prostate cancer
    Oh, WK
    DRUGS, 2005, 65 (16) : 2296 - 2297
  • [8] Safety and antitumor efficacy of 153Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer
    Borso, Elisa
    Boni, Giuseppe
    Pastina, Ilaria
    Lorenzoni, Alice
    Cianci, Claudia
    Federici, Francesca
    Mazzarri, Sara
    Orlandini, Cinzia
    Francesca, Francesco
    Selli, Cesare
    Ricci, Sergio
    Rubello, Domenico
    Mariani, Giuliano
    NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (01) : 88 - 94
  • [9] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
    Vordos, D
    Paule, B
    Vacherot, F
    Allory, Y
    Salomon, L
    Hoznek, A
    Yiou, R
    Chopin, D
    Abbou, CC
    de la Taille, A
    BJU INTERNATIONAL, 2004, 94 (04) : 524 - 527
  • [10] Combining 153Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience
    Suttmann, Henrik
    Grgic, Aleksandar
    Lehmann, Jan
    Zwergel, Ulrike
    Kamradt, Joern
    Gouverneur, Eric
    Pinkert, Joerg
    Stoeckle, Michael
    Kirsch, Carl-Martin
    Nestle, Ursula
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (05) : 609 - 618
12345